Spectranetics Corporation (SPNC) Drops 9.2% on January 28

Equities Staff  |

Spectranetics Corporation (SPNC) was one of the Russell 2000's biggest losers for Thursday January 28 as the stock slid 9.2% to $11.84, a loss of $-1.2 per share. Starting at an opening price of $13.13 a share, the stock traded between $11.74 and $13.13 over the course of the trading day. Volume was 742,799 shares over 4,911 trades, against an average daily volume of 679,152 shares and a total float of 42.64 million.

The losses send Spectranetics Corporation down to a market cap of $504.82 million. In the last year, Spectranetics Corporation has traded between $37.04 and $10.65, and its 50-day SMA is currently $14.27 and 200-day SMA is $18.60.

The Spectranetics Corp develops, manufactures, markets and distributes single-use medical devices. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart and to remove pacemaker and defibrillator cardiac leads.

Spectranetics Corporation is based out of Colorado Springs, CO and has some 753 employees. Its CEO is Scott Drake.

For a complete fundamental analysis analysis of Spectranetics Corporation, check out Equities.com’s Stock Valuation Analysis report for SPNC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

DirectView Holdings Inc

DirectView Holdings Inc designs and installs surveillance systems, digital video recording and services. The company through its subsidiaries operates within two divisions security and surveillance and video conferencing services.